Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: review decision - April 2013 information

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 195 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - guidance development (PDF 74 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final appraisal determination  information

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final appraisal determination document (PDF 283 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: evaluation report

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: pre-meeting briefing (PDF 636 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report (PDF 2.8 MB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report - factual accuracy check (PDF 138 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: erratum to the Evidence Review Group report

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: erratum (PDF 277 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: post-Appraisal Committee meeting erratum (PDF 182 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Bristol-Myers Squibb and Pfizer (PDF 8.52 MB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: clarification

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: NICE clarification letter to the manufacturer (PDF 239 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Bristol-Meyers Squibb and Pfizer response to clarification points (PDF 976 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: patient group, professional and NHS organisation submission statements

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: AntiCoagulant Europe (PDF 76 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Arrhythmia Alliance (PDF 192 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Clinical Leader of Thrombosis (PDF 258 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Heart Rhythm UK (PDF 103 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Royal College of Nursing (PDF 55 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Royal College of Physicians and British Society of Haematology (PDF 93 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: expert written personal statements

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Diane Eaton - appendix K patient/carer declaration statement (PDF 31 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Jo Jerrome - appendix K patient/carer declaration statement (PDF 209 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Professor Gregory Lip - appendix D clinical specialist statement (PDF 98 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Francis Murgatroyd - appendix K clinical specialist statement (PDF 25 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Watts - appendix K clinical specialist statement (PDF 26 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the provisional matrix - June 2012 (PDF 46 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the draft remit and draft scope - June 2012 (PDF 224 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final scope - June 2012 (PDF 51 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final matrix - June 2012 (PDF 51 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - scoping - June 2012 (PDF 47 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - provisional matrix February 2012 (PDF 34 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - draft scope for consultation (pre-referral) July 2011 (PDF 57 KB)

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - draft scope for consultation (pre-referral) July 2011 (PDF 57 KB)